ライフサイエンスコーパス: pericarditis

1 s been implicated as a mediator of recurrent pericarditis.

2 in a phase II study in recurrent/refractory pericarditis.

3 ociated with increased risk for constrictive pericarditis.

4 period, there were 1361 admissions for acute pericarditis.

5 is effective for the treatment of recurrent pericarditis.

6 levation of biomarkers to myocarditis and/or pericarditis.

7 ve treatment for posttransplant constrictive pericarditis.

8 y reduced the rate of incessant or recurrent pericarditis.

9 ary study outcome was incessant or recurrent pericarditis.

10 ressed to cardiac tamponade and constrictive pericarditis.

11 s for pericardial effusions and constrictive pericarditis.

12 also to suggest a diagnosis of constrictive pericarditis.

13 and development of severe grossly detectable pericarditis.

14 t observed in clinical cases of constrictive pericarditis.

15 resents a novel animal model of constrictive pericarditis.

16 essential diagnostic feature of constrictive pericarditis.

17 rdiomyopathy and preserved with constrictive pericarditis.

18 common finding in patients with constrictive pericarditis.

19 induced AF episodes in six dogs with sterile pericarditis.

20 ly in symptomatic patients with constrictive pericarditis.

21 ients who had surgically proved constrictive pericarditis.

22 ch is not seen in patients with constrictive pericarditis.

23 trictive compared with those in constrictive pericarditis.

24 a valuable adjunct in assessing constrictive pericarditis.

25 n patients with incident viral or idiopathic pericarditis.

26 er echocardiographic feature in constrictive pericarditis.

27 ult for a patient with Staphylococcus aureus pericarditis.

28 in relation to the diagnosis of constrictive pericarditis.

29 ist in noninvasively diagnosing constrictive pericarditis.

30 cles published until April 2022 on recurrent pericarditis.

31 se 2 trial involving patients with recurrent pericarditis.

32 0.1%-0.5%) experienced acute myocarditis or pericarditis.

33 aradigm shift in the management of recurrent pericarditis.

34 prevent recurrence and effusive-constrictive pericarditis.

35 ignal was identified for only myocarditis or pericarditis.

36 low-up encounters after the first episode of pericarditis.

37 icacy of interleukin-1 blockers in recurrent pericarditis.

38 ), 10 patients (0.8%) developed constrictive pericarditis.

39 presenting with apparent viral or idiopathic pericarditis.

40 ere were no reports of either myocarditis or pericarditis.

41 tment for patients with recurrent/refractory pericarditis.

42 t is indicated for the treatment of gout and pericarditis.

43 comparison cohort of cancer patients without pericarditis.

44 up-to-date management of acute and recurrent pericarditis.

45 stant and corticosteroid-dependent recurrent pericarditis.

46 stant and corticosteroid-dependent recurrent pericarditis.

47 atients who present with idiopathic or viral pericarditis.

48 with NSAIDs may reduce readmission rates for pericarditis.

49 ine for treatment of multiple recurrences of pericarditis.

50 equiring pericardiocentesis, or constrictive pericarditis.

51 ssociated with the diagnosis of constrictive pericarditis.

52 equiring pericardiocentesis, or constrictive pericarditis.

53 i immunotherapy in patients with tuberculous pericarditis.

54 uced myocarditis (14.1 to 43.1%, P < 0.001); pericarditis (1.5 to 7.6%, P < 0.001); fibrosis (9.7 to

55 e independently associated with constrictive pericarditis: (1) ventricular septal shift, (2) medial m

56 Among 13 759 patients with acute pericarditis, 1550 subsequently were diagnosed with canc

57 inflammatory heart disease (myocarditis, 3; pericarditis, 2) that resulted in restriction from play.

58 sociated with the development of complicated pericarditis; 2) in select cases, cardiovascular magneti

59 Two days after creation of sterile pericarditis, 24 dogs underwent either a four-part or fi

60 (13), recurrent sternal depression (5), and pericarditis (3).

61 orded more frequently in patients with acute pericarditis (32%) than in those with myopericarditis (1

62 induced AF episodes in six dogs with sterile pericarditis, 372 unipolar electrograms were recorded si

63 disease without an overlap with constrictive pericarditis (39.5+/-18.8 cm/s vs. 4.2+/-3.4 cm/s, p < 0

64 reductions in the incidence of constrictive pericarditis (4.4% vs. 7.8%; hazard ratio, 0.56; 95% CI,

65 81.17-85.33]; IC, 3.96 [IC(025), 3.94]) and pericarditis (42.16 [41.19-43.16]; 3.66 [3.64]).

66 nitis (16%), sternal osteomyelitis (6%), and pericarditis (6%).

67 pansion (Ea) in 8 patients with constrictive pericarditis, 7 patients with restriction and 15 normal

68 CVD (dysrhythmia, valvular dysfunction, and pericarditis) (adjusted, 1.29 [1.11-1.50]) in women who

69 tistical signals detected for myocarditis or pericarditis after BNT162b2 (ages 12-17 years) were cons

70 arditis are idiopathic or viral, followed by pericarditis after cardiac procedures or operations.

71 r institutional experience with constrictive pericarditis after lung transplant in an effort to inves

72 ntify variables associated with constrictive pericarditis after lung transplantation.

73 tantial number of patients with constrictive pericarditis after pericardiectomy.

74 signal was observed only for myocarditis or pericarditis after primary series vaccination with BNT16

75 An increased risk of myocarditis or pericarditis after priming with mRNA Coronavirus Disease

76 e Anakinra-Treatment of Recurrent Idiopathic Pericarditis (AIRTRIP) double-blind, placebo-controlled,

77 tic ECG changes, pericarditic chest pain, or pericarditis (all P>0.05).

78 patients with surgically proven constrictive pericarditis, although the histopathological appearance

79 ncrease in the occurrence of myocarditis and pericarditis among those vaccinated.

80 ients with surgically confirmed constrictive pericarditis and 12 patients (control subjects) with hea

81 Sixteen of the 20 patients had tuberculous pericarditis and 4 patients had other diagnoses.

82 raphic data of 50 patients with constrictive pericarditis and 44 with restrictive cardiomyopathy were

83 We identified 7,988 patients with pericarditis and 79,880 matched control individuals.

84 e and found that rIL-33 induced eosinophilic pericarditis and adversely affected heart function.

85 as more likely within 1 year of the onset of pericarditis and among younger patients, those with unco

86 3 therapeutic approaches on the incidence of pericarditis and atrial fibrillation (AF) after percutan

87 ecimens (70%) from patients with tuberculous pericarditis and by PCR in 14 of 28 specimens (50%) from

88 Constrictive pericarditis and chronic obstructive pulmonary disease h

89 vival probability was 92.9% and 95.8% in the pericarditis and control groups, respectively (adjusted

90 3% +/- 6% and -8% +/- 7% in the constrictive pericarditis and control groups, respectively (p < 0.000

91 ericardiectomy in patients with constrictive pericarditis and correlated postoperative Doppler echoca

92 cine is effective for the treatment of acute pericarditis and first recurrences.

93 d a mycotic right atrial pseudoaneurysm with pericarditis and hemopericardium, without gross or patho

94 of colchicine during a first attack of acute pericarditis and in the prevention of recurrent symptoms

95 Pericardial heart disease comprises only pericarditis and its complications, tamponade and constr

96 are increased in patients with constrictive pericarditis and may be helpful in diagnosing this condi

97 ic similarities between recurrent idiopathic pericarditis and periodic fever syndromes, disorders of

98 ally useful distinction between constrictive pericarditis and restrictive cardiomyopathy and may prov

99 erived from patients with known constrictive pericarditis and restrictive cardiomyopathy.

100 easures: The primary outcomes were recurrent pericarditis and time to recurrence after randomization.

101 cardiogram (ECG), arrhythmias, ischemia, and pericarditis and/or myocarditis-like syndromes, or they

102 ngestive heart failure, 2 were attributed to pericarditis, and 1 was attributed to pulmonary embolism

103 respiratory tract and lead to airsacculitis, pericarditis, and colisepticemia.

104 ations, hospital diagnoses of myocarditis or pericarditis, and covariates for the participants were o

105 e development of severe chronic myocarditis, pericarditis, and DCM after CB3 infection by reducing MC

106 ant opportunity to evaluate for constrictive pericarditis, and definite diagnostic criteria are neede

107 al ingredient widely used for treating gout, pericarditis, and familial Mediterranean fever with high

108 lar dysfunction, vasculitis, myocarditis and pericarditis, and heart failure.

109 inra also improved outcomes in patients with pericarditis, and it is now considered standard of care

110 of myocardial disease further confirmed that pericarditis, and not myocarditis, was responsible for s

111 ized infection manifesting as perihepatitis, pericarditis, and septicemia.

112 , a minority of patients develop complicated pericarditis, and the care of these patients is the focu

113 tern Europe, the most common causes of acute pericarditis are idiopathic or viral, followed by perica

114 Patients hospitalized for acute pericarditis are more commonly male.

115 lae, including left ventricular thrombus and pericarditis, are easily identified.

116 other thromboembolic events, myocarditis or pericarditis, arrhythmia, kidney injury, appendicitis, a

117 was suspected with atypical ECG changes for pericarditis, arrhythmias, and cardiac troponin elevatio

118 in patients with acute symptoms of recurrent pericarditis (as assessed on a patient-reported scale) a

119 apy for gout and a second-line treatment for pericarditis, as well as a basic part of familial Medite

120 deficient mice developed a fibrous, adhesive pericarditis associated with increased numbers of degran

121 e main diagnostic criterion for constrictive pericarditis by Doppler echocardiography, it can also be

122 esult in camptodactyly-arthropathy-coxa vara-pericarditis (CACP) syndrome, which is characterized pri

123 ing delivery of atrial shocks in the sterile pericarditis canine model of atrial fibrillation.

124 modelling, atherothrombosis, myocarditis and pericarditis, cardiotoxicity and cardiac sarcoidosis).

125 Acute pericarditis caused 0.20% (95% CI, 0.19%-0.22%) of all c

126 The proportion of pericarditis-caused admissions declined by an estimated

127 (<0.36) for dysrhythmia, ambulation status, pericarditis, chronic obstructive pulmonary disease, and

128 naphylaxis, acute myocardial infarction, myo/pericarditis, coagulopathy, multisystem inflammatory syn

129 In patients with acute pericarditis, colchicine, when added to conventional ant

130 incidence ratios of cancer for patients with pericarditis compared with the general population.

131 One patient had grade 2 pericarditis consistent with radiation recall, and one p

132 Elevated risks of arrhythmia, pericarditis, coronary artery disease, stroke, and valvu

133 ful for differentiating chronic constrictive pericarditis (CP) and restrictive cardiomyopathy (RCM).

134 PV) velocities in patients with constrictive pericarditis (CP) and to describe the influence of atria

135 Differentiation of constrictive pericarditis (CP) from restrictive cardiomyopathy (RCM)

136 ) measurements to differentiate constrictive pericarditis (CP) from restrictive cardiomyopathy (RCMP)

137 The clinical spectrum of constrictive pericarditis (CP) has been affected by a change in incid

138 Constrictive pericarditis (CP) is a disabling disease, and usually re

139 ictive cardiomyopathy (RCM) and constrictive pericarditis (CP) is challenging and, despite combined i

140 n criteria for the diagnosis of constrictive pericarditis (CP) rely on equalization of intracardiac p

141 compare myocardial mechanics of constrictive pericarditis (CP) with restrictive cardiomyopathy (RCM),

142 criterion for the diagnosis of constrictive pericarditis (CP), but simultaneous ventricular measurem

143 In constrictive pericarditis (CP), E' is not reduced, despite increased

144 the association of etiology of constrictive pericarditis (CP), pericardial calcification (CA), and o

145 criterion for the diagnosis of constrictive pericarditis (CP).

146 nd natural history of transient constrictive pericarditis (CP).

147 Incidence of acute severe pericarditis delayed pericardial effusion and gastrointe

148 us scleroderma in whom calcific constrictive pericarditis developed.

149 ctive surveillance of MVA recipients for myo/pericarditis did not detect cardiac adverse reactions in

150 Corticosteroids are often used if pericarditis does not improve with NSAIDs and colchicine

151 all patients with a first-time diagnosis of pericarditis during 1994 to 2013.

152 All patients had chest pain consistent with pericarditis early after the procedure that resolved wit

153 onacept led to rapid resolution of recurrent pericarditis episodes and to a significantly lower risk

154 rditis except in just one case of autoimmune pericarditis); especially all of the SUVmax scores >= 10

155 ncident myocarditis events and 1149 incident pericarditis events were identified.

156 pically indicates tuberculosis or neoplastic pericarditis except in just one case of autoimmune peric

157 cardiectomy, some patients with constrictive pericarditis fail to improve postoperatively.

158 and had a reported episode of myocarditis or pericarditis following receipt of the COVID-19 vaccine d

159 ts discharged with a first-time diagnosis of pericarditis from 1996 to 2016.

160 have included: differentiating constrictive pericarditis from restriction, estimation of left ventri

161 velocity to help differentiate constrictive pericarditis from restrictive cardiomyopathy.

162 n velocities in differentiating constrictive pericarditis from restrictive cardiomyopathy.

163 s evaluated for differentiating constrictive pericarditis from restrictive cardiomyopathy.

164 raphy allows differentiation of constrictive pericarditis from restrictive myocardial disease and sev

165 mission-required diagnosis was higher in the pericarditis group both for cardiovascular and noncardio

166 a higher mortality risk over 5 years in the pericarditis group, especially among the female patients

167 rom 26.4 +/- 24.2 to 8.8 +/- 22.6 min in the pericarditis group, p = 0.02, and from 33.7 +/- 29.2 to

168 Adult patients with multiple recurrences of pericarditis (>/=two) were randomly assigned (1:1) to pl

169 Most patients with acute pericarditis have a benign course and a good prognosis.

170 topathology for the diagnosis of tuberculous pericarditis in 36 specimens of pericardial fluid and 19

171 tures, including ulcerations in children and pericarditis in adults.

172 Tuberculosis is a major cause of pericarditis in developing countries but accounts for le

173 st common treatment for idiopathic and viral pericarditis in North America and Europe is NSAID therap

174 tructive pulmonary disease from constrictive pericarditis in patients with a respiratory variation of

175 in radiograph strongly suggests constrictive pericarditis in patients with heart failure.

176 educed the rate of subsequent recurrences of pericarditis in patients with multiple recurrences.

177 f and risk factors associated with recurrent pericarditis in patients with SLE were unknown.

178 cines were reported to cause myocarditis and pericarditis in rare cases, but the use of novel mRNA pl

179 term impacts associated with myocarditis and pericarditis in relation to drug.

180 line treatment for either acute or recurrent pericarditis in the absence of contraindications or spec

181 The primary outcome was recurrent pericarditis in the intention-to-treat population.

182 cant advance in medical therapy of recurrent pericarditis in the last 5 years.

183 eviated atrial remodeling, abrogated sterile pericarditis-induced inhomogeneous conduction, and preve

184 Idiopathic recurrent pericarditis (IRP) is a rare autoinflammatory disease.

185 Acute pericarditis is a common cause of nonischemic chest pain

186 Viral or idiopathic pericarditis is a frequent condition, often considered b

187 Constrictive pericarditis is a potentially reversible cause of heart

188 Constrictive pericarditis is a rare, but increasingly recognized long

189 , although prior studies have suggested that pericarditis is associated with both cardiovascular and

190 Tuberculous pericarditis is associated with high morbidity and morta

191 However, calcific constrictive pericarditis is considered rare in the United States sin

192 Acute pericarditis is diagnosed with presence of 2 or more of

193 A physiologic hallmark of constrictive pericarditis is enhanced ventricular interdependence, wh

194 Acute pericarditis is generally self-limited and not life-thre

195 atients who have been hospitalized for acute pericarditis is largely uncharacterized.

196 The mainstay of treatment of pericarditis is represented by anti-inflammatory drugs.

197 Pericarditis is the most common form of pericardial dise

198 Pericarditis is the most common form of pericardial dise

199 Constrictive pericarditis is the result of a spectrum of primary card

200 In North America and Western Europe, pericarditis is typically idiopathic, develops after a v

201 ericarditis, the development of constrictive pericarditis (<0.5%) and pericardial tamponade (<3%) can

202 Pericarditis may be a marker of occult cancer and augurs

203 Pericarditis may be a serious complication of malignancy

204 The etiology of pericarditis may be infectious (eg, viral and bacterial)

205 All reports of myocarditis or pericarditis meeting levels 1 to 3 of the Brighton Colla

206 evidence of symptomatic or asymptomatic myo/pericarditis meeting the CDC-case definition and judged

207 ed, there were 297 reports of myocarditis or pericarditis meeting the inclusion criteria; 228 (76.8%)

208 f atrial fibrillation were used: the sterile pericarditis model (n = 10) and the rapid atrial pacing

209 A sterile pericarditis model was created using atrial surfaces dus

210 In the canine sterile pericarditis model, the mechanisms of maintenance of AF

211 of the onset of atrial flutter in the canine pericarditis model, we suggest that a transitional rhyth

212 ural effusion (n = 7), pneumothorax (n = 2), pericarditis (n = 2), dislodged sternal bar (n = 3), and

213 eural empyema (n = 4), lung abscess (n = 7), pericarditis (n = 2), osteomyelitis (n = 5), meningitis/

214 eritoneal disease (n = 10), and constrictive pericarditis (n = 2).

215 of the procedure included tamponade (n = 4), pericarditis (n = 3), heart block (n = 1, prior to radio

216 ients with surgically confirmed constrictive pericarditis (n=130) at Mayo Clinic (2008-2010) were com

217 infarction [n = 5], unstable angina [n = 3], pericarditis [n = 2], arrhythmia [n = 12], and heart fai

218 m, anaphylaxis, Bell's palsy, myocarditis or pericarditis, narcolepsy, appendicitis, immune thrombocy

219 In patients with tuberculous pericarditis, neither prednisolone nor M. indicus pranii

220 hat has been labeled "transient constrictive pericarditis." No large studies have examined the causes

221 Recurrent pericarditis occurred in 9 of 10 patients (90%; incidenc

222 tep with anakinra or placebo until recurrent pericarditis occurred) conducted among 21 consecutive pa

223 ars; range, 18-83 years; 300 men) with acute pericarditis or a myopericardial inflammatory syndrome (

224 CDC-case definition for vaccinia-related myo/pericarditis or who experienced cardiac adverse events f

225 2) in the heart, cardiomyopathy, symptomatic pericarditis, or an arrhythmia requiring treatment; 3) i

226 A total of 411 myocarditis or pericarditis, or both, events were observed among 15 148

227 such as rheumatic heart disease, tuberculous pericarditis, or cardiomyopathy and others having a mark

228 oplastic infiltration, effusive-constrictive pericarditis, or loculated effusions, fluoroscopic guida

229 ecimens (50%) from patients with tuberculous pericarditis (P > 0.15).

230 Pericarditis (P = 0.009), pulmonary hypertension (P < 0.

231 A total of 86 patients with pericarditis pain and an elevated CRP level were enrolle

232 Pericarditis patients were more likely to be male (64.9%

233 in-hospital mortality in hospitalized acute pericarditis patients.

234 extraarticular RA manifestations (including pericarditis, pleuritis, and vasculitis) were recorded a

235 Adverse events included severe pericarditis post-operatively (n = 2), late pericardial

236 rs admitted to the hospital because of acute pericarditis (postpericardiotomy and myocardial infarcti

237 We assessed whether pericarditis predicts cancer survival by the Kaplan-Meie

238 the presence of grossly detectable adhesive pericarditis present only in the KO group and characteri

239 cardial infarction, thyrotoxicosis, alcohol, pericarditis, pulmonary embolism, and myocarditis).

240 l hypertension, hypertrophic cardiomyopathy, pericarditis, pulmonary embolism, hepatic granulomatous

241 Disease Control and Prevention, myocarditis/pericarditis rates are 12.6 cases per million doses of s

242 d miR-21, were highly upregulated in sterile pericarditis rats.

243 pisodes and to a significantly lower risk of pericarditis recurrence than placebo.

244 Patients presenting with pericarditis recurrence while receiving standard therapy

245 patients (7%) in the rilonacept group had a pericarditis recurrence, as compared with 23 of 31 patie

246 nal-hazards model, was the time to the first pericarditis recurrence.

247 to placebo (n = 10) for 6 months or until a pericarditis recurrence.

248 , 120 patients (20.3%) experienced recurrent pericarditis (recurrence rate = 0.053 recurrences; 95% C

249 Pericarditis refers to the inflammation of the pericardi

250 6 to 65 years of age were at higher risk for pericarditis (relative risk, 2.02; 95% CI, 1.81-2.26; P<

251 ing the evaluation of suspected constrictive pericarditis, repeat Doppler recording of mitral flow ve

252 Constrictive pericarditis represents a serious hemodynamic syndrome t

253 was 80% and 86% among those with and without pericarditis, respectively, and the hazard ratio was 1.5

254 t, type 2 diabetes, heart failure, recurrent pericarditis, rheumatoid arthritis, and smoldering myelo

255 Among patients with recurrent pericarditis, rilonacept led to rapid resolution of recu

256 r (2 patients), generator migration (1), and pericarditis secondary to the epicardial patches (1).

257 th cardiac involvement (2 endocarditis and 1 pericarditis), secondary to intravenous bath salts use.

258 Diagnosis of constrictive pericarditis should be considered in patients with new-o

259 ricardial effusion, acute coronary syndrome, pericarditis, significant arrhythmia, and heart failure)

260 with differences in rates of myocarditis or pericarditis specific to vaccine products, which may hav

261 disorder camptodactyly-arthropathy-coxa vara-pericarditis syndrome (CACP).

262 disorder camptodactyly-arthropathy-coxa vara-pericarditis syndrome (CACP; MIM 208250) to identify bio

263 disorder camptodactyly-arthropathy-coxa vara-pericarditis syndrome.

264 ipoarabinomannan (LAM) assays in tuberculous pericarditis (TBP).

265 and may identify patients with constrictive pericarditis that will improve with anti-inflammatory th

266 In acute pericarditis, the development of constrictive pericardit

267 In tamponade caused by acute pericarditis, the patient can experience fever and typic

268 adults with definite or probable tuberculous pericarditis to either prednisolone or placebo for 6 wee

269 In patients with constrictive pericarditis treated with anti-inflammatory therapy, a q

270 rdiovascular complications (one constrictive pericarditis, two right heart failures without underlyin

271 95, a total of 58 patients with constrictive pericarditis underwent pericardiectomy and had at least

272 The in-hospital mortality rate for acute pericarditis was 1.1% (95% CI, 0.6%-1.8%).

273 The <3-month cancer risk among patients with pericarditis was 2.7%, and the standardized incidence ra

274 The proportion of patients who had recurrent pericarditis was 26 (21.6%) of 120 in the colchicine gro

275 incidence rate of hospitalizations for acute pericarditis was 3.32 per 100 000 person-years.

276 The diagnosis of acute pericarditis was based on the presence of 2 of 4 clinica

277 Constrictive pericarditis was confirmed by the surgical report.

278 In 21 patients (3.6), the diagnosis of pericarditis was confirmed via electrocardiogram or dedi

279 e tricuspid regurgitation after constrictive pericarditis was considered but ruled out.

280 An increased risk of myocarditis or pericarditis was observed after COVID-19 mRNA vaccinatio

281 Vaccinia-associated myo/pericarditis was observed during the US smallpox vaccina

282 An elevated risk of admission for pericarditis was only observed 0 to 6 days after a secon

283 asymptomatic, and no specific treatment for pericarditis was started.

284 ryopreserved specimens from a prior study of pericarditis, we compared PCR to culture and histopathol

285 diotomy and myocardial infarction associated pericarditis were excluded).

286 Although myocarditis and pericarditis were not observed as adverse events in coro

287 hritis, discoid lesions, or pleuritis and/or pericarditis were randomized at a ratio of 2:1 to receiv

288 en patients who responded with resolution of pericarditis were randomized to continue anakinra (n = 1

289 uble-blind trial, eligible adults with acute pericarditis were randomly assigned to receive either co

290 ak inspiration in patients with constrictive pericarditis were significantly different from those in

291 Estimates for pericarditis were similar.

292 Recurrences (mainly as recurrent pericarditis) were the most common complication during f

293 ur knowledge that IL-33 induces eosinophilic pericarditis, whereas soluble ST2 prevents eosinophilia

294 ients with surgically confirmed constrictive pericarditis who had < 25% respiratory variation in mitr

295 ed 41 consecutive patients with constrictive pericarditis who had a cardiovascular magnetic resonance

296 6 locations in 11 patients with constrictive pericarditis who underwent intraoperative transesophagea

297 preliminary study of patients with recurrent pericarditis with colchicine resistance and corticostero

298 dependent and colchicine-resistant recurrent pericarditis with evidence of systemic inflammation, as

299 Included patients had recurrent pericarditis (with >/=3 previous recurrences), elevation

300 undergoing pericardiectomy for constrictive pericarditis without tricuspid valve surgery and with pr